NuVasive Specialized Orthopedics (NSO) received FDA 510(k) clearance for the use of its Precice all-internal limb lengthening solution to include pediatric patients. The expanded clearance extends the clinical benefits of Precice to a wider range of patients.
Precice is a magnetically adjustable technology that utilizes an external remote to non-invasively lengthen implants. The Precice nail has been implanted more than 15,000 times, by more than 2,000 surgeons, and in nearly 50 countries. As a division of NuVasive, NSO is focused on the design and innovation of disruptive orthopedic solutions for complex orthopedic reconstruction and limb lengthening.
Furthering the company’s ability to treat the full continuum of care, the next phase of NSO’s orthopedic innovation is intelligent surgery. The company’s asset acquisition efforts in December 2022 position NSO as an early player in next-generation motorized technology for dynamic orthopedic implants. (In December 2022, NuVasive purchased assets from ENDOTACT.)
NuVasive Specialized Orthopedics (NSO) received FDA 510(k) clearance for the use of its Precice all-internal limb lengthening solution to include pediatric patients. The expanded clearance extends the clinical benefits of Precice to a wider range of patients.
Precice is a magnetically adjustable technology that utilizes an external remote to...
NuVasive Specialized Orthopedics (NSO) received FDA 510(k) clearance for the use of its Precice all-internal limb lengthening solution to include pediatric patients. The expanded clearance extends the clinical benefits of Precice to a wider range of patients.
Precice is a magnetically adjustable technology that utilizes an external remote to non-invasively lengthen implants. The Precice nail has been implanted more than 15,000 times, by more than 2,000 surgeons, and in nearly 50 countries. As a division of NuVasive, NSO is focused on the design and innovation of disruptive orthopedic solutions for complex orthopedic reconstruction and limb lengthening.
Furthering the company’s ability to treat the full continuum of care, the next phase of NSO’s orthopedic innovation is intelligent surgery. The company’s asset acquisition efforts in December 2022 position NSO as an early player in next-generation motorized technology for dynamic orthopedic implants. (In December 2022, NuVasive purchased assets from ENDOTACT.)
Copy to clipboard 
